hUC-MSC
/ Shenzhen Wingor Biotechnology
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 21, 2026
Phase ?/?a Trial Evaluating Intravenous hUC-MSCs Injection for Safety, Tolerability and Efficacy in Patients With POI
(clinicaltrials.gov)
- P1/2 | N=59 | Recruiting | Sponsor: Shenzhen Wingor Biotechnology Co., Ltd.
New P1/2 trial • Women's Health
July 29, 2026
A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS
(clinicaltrials.gov)
- P2 | N=60 | Recruiting | Sponsor: Shenzhen Wingor Biotechnology Co., Ltd. | Trial completion date: Dec 2026 ➔ Dec 2028 | Trial primary completion date: Mar 2026 ➔ May 2027
Trial completion date • Trial primary completion date • Cardiovascular • Ischemic stroke
September 30, 2025
A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS
(clinicaltrials.gov)
- P2 | N=60 | Recruiting | Sponsor: Shenzhen Wingor Biotechnology Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Cardiovascular • Ischemic stroke
July 25, 2025
A Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Intravenous Infusion of hUC-MSCs in Patients With AIS
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: Shenzhen Wingor Biotechnology Co., Ltd.
New P2 trial • Cardiovascular • Ischemic stroke
1 to 4
Of
4
Go to page
1